Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18085918 | 0.88 | HDAC3 (0.63) | SMN1; SMN2HTTNPC1RAB9AHDAC3 | |
| SCHEMBL18085912 | 0.87 | HDAC3 (0.64) | SMN1; SMN2HTTNPC1RAB9AHDAC3 | |
| SCHEMBL18534318 | 0.85 | NPC1 (0.56) | SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL10174286 | 0.84 | NPC1 (0.59) | SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL29300259 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTNPC1RAB9AHDAC3 | |
| SCHEMBL29299615 | 0.83 | NPC1 (0.54) | SMN1; SMN2HTTNPC1RAB9AALDH1A1 | |
| SCHEMBL10099539 | 0.83 | L3MBTL1 (0.69) | SMN1; SMN2NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL12650598 | 0.83 | NAAA (0.66) | SMN1; SMN2NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL10099538 | 0.82 | HDAC3 (0.61) | SMN1; SMN2NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL11282161 | 0.82 | NPC1 (0.53) | SMN1; SMN2NPC1RAB9AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | SMN1; SMN2 3725/4885HTT 1975/4885NPC1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.